Search Results

You are looking at 121 - 130 of 203 items for :

  • "lymph node dissection" x
  • Refine by Access: All x
Clear All
Full access

Douglas B. Johnson and Jeffrey A. Sosman

patient underwent a completion axillary lymph node dissection with 2 additional lymph nodes with melanoma involvement; extracapsular extension was not identified (TxN2b; AJCC stage IIIB). Detailed physical examination did not reveal a primary site of

Full access

Eleni Efstathiou and Christopher J. Logothetis

-chemotherapy retroperitoneal lymph node dissection . Br J Cancer 1999 ; 80 : 249 – 255 . 55. Howell SJ Shalet SM . Spermatogenesis after cancer treatment: damage and recovery . J Natl Cancer Inst Monogr 2005 ; 34 : 12 – 17 . 56. Brydoy M Fossa SD

Full access

Kevin S. Scher, Juan-Sebastian Saldivar, Michael Fishbein, Alberto Marchevsky, and Karen L. Reckamp

node dissection. Pathology results showed a moderately differentiated adenocarcinoma without evidence of squamous histology in any of the specimens. Margins were focally positive at the hilar and perivascular soft tissue margin. Of the 10 sampled lymph

Full access

Daniel G. Coit, John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Adil Daud, Dominick DiMaio, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Mary C. Martini, Anthony J. Olszanski, Merrick I. Ross, April Salama, Susan M. Swetter, Kenneth K. Tanabe, Vijay Trisal, Marshall M. Urist, Nicole R. McMillian, and Maria Ho

as an isolated site of relapse underwent therapeutic lymph node dissection followed by either adjuvant radiation to the nodal basin or observation. 5 Eligible patients were required to have a lactate dehydrogenase (LDH) level less than 1.5 times the

Full access

Presenters: Meena S. Moran and A. Marilyn Leitch

avoidance of axillary lymph node dissection (ALND) in many patients. This recommendation is largely based on findings from ACOSOG Z0011 and SINODAR-ONE, in which patients with clinical T1/T2N0 disease with up to 2 positive sentinel nodes fared equally well

Full access

Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell

with retroperitoneal lymph node dissection only? Which patients with stage II and III disease will need to undergo resection of residual masses after chemotherapy?” he continued. Dr. Gilligan explained that the 8th edition has made some changes, but

Full access

Saranya Chumsri, Ethan S. Sokol, Aixa E. Soyano-Muller, Ricardo D. Parrondo, Gina A. Reynolds, Aziza Nassar, and E. Aubrey Thompson

subsequently underwent right modified radical mastectomy with axillary lymph node dissection. Pathology results showed multifocal residual disease measuring up to 16.5 cm, with >10 additional satellite tumors and skin involvement. Among resected axillary lymph

Full access

Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse

omental caking. CA-125 serum tumor marker at time of presentation was elevated at 1,155 kU/L (normal range, <35 kU/L). The patient underwent primary surgery with radical hysterectomy, bilateral salpingo-oophorectomy, lymph node dissection, and removal of

Full access

John J. Stocking, Michael V. Fiandalo, Elena A. Pop, John H. Wilton, Gissou Azabdaftari, and James L. Mohler

extrafascial radical prostatectomy, and right pelvic lymph node dissection revealed Gleason grade 3+4=7 adenocarcinoma that occupied 5% of a 20-gram prostate. Gleason grade was overestimated due to prostate biopsy undersampling, which occurs rarely. 9

Full access

Michelle C. Nguyen, Manisha H. Shah, David A. Liebner, Floor J. Backes, John Phay, and Lawrence A. Shirley

-oophorectomy and pelvic and periaortic lymph node dissection for stage III uterine carcinosarcoma in March 2016. She completed 6 cycles of carboplatin and paclitaxel therapy and 4,860 cGy of RT to the pelvic and aortic nodes. She later developed subcutaneous